Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Reexamination Certificate
2001-05-18
2003-02-25
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
C424S204100, C424S278100, C424S280100, C435S235100
Reexamination Certificate
active
06524586
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Technical Field
The present invention relates to covalent modification of surface protein or carbohydrate of a virus for enhancing immunogenicity of the virus.
2. Related Art
A vaccine inoculation administered to a person may comprise a live attenuated virus (e.g., a polio virus) for eliciting an immune response that enables the person to develop an immunity to being subsequently infected by the virus. Although the vaccine may be effective for a majority of people so inoculated, unfortunately a small percentage of people so inoculated actually develop the viral disease associated with the virus. Thus, it is desirable to maintain or enhance the effectiveness of the vaccine for immunization purposes, while at the same time reduce or eliminate the risk of contracting the viral disease as a result of being inoculated by the vaccine.
SUMMARY OF THE INVENTION
The present invention provides a method for forming a viral-physiological structure, comprising:
providing a naked virus having a capsid; and
covalently bonding a linker molecule to the capsid, wherein a polymer is covalently attached to the linker molecule to form a polymer-protected virus, and wherein an immunogenicity of the polymer-protected virus with respect to an animal exceeds an immunogenicity of the naked virus with respect to the animal.
The present invention provides a viral-physiological structure, comprising:
a naked virus having a capsid; and
means for covalently bonding a linker molecule to the capsid, wherein a polymer is covalently attached to the linker molecule to form a polymer-protected virus, and wherein an immunogenicity of the polymer-protected virus with respect to an animal exceeds an immunogenicity of the naked virus with respect to the animal.
The present invention provides a viral-physiological structure, comprising:
a naked virus having a capsid; and
a linker molecule covalently bonded to the capsid, wherein a polymer is covalently attached to the linker molecule to form a polymer-protected virus, and wherein an immunogenicity of the polymer-protected virus with respect to an animal exceeds an immunogenicity of the naked virus with respect to the animal.
The present invention maintains or enhances the effectiveness of a vaccine for immunizing a person or non-human animal to viral disease associated with a virus, while at the same time reduces or eliminates the risk of contracting the viral disease as a result of being inoculated by the vaccine.
REFERENCES:
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 5204243 (1993-04-01), Paoletti
patent: 5569468 (1996-10-01), Modi
patent: 5908624 (1999-06-01), Scott et al.
patent: 5969109 (1999-10-01), Bona et al.
patent: 6136321 (2000-10-01), Barrett et al.
patent: 402067227 (1990-03-01), None
O'Riordan et al (Human Gene Therapy 10:1349-1358, 1999).*
Croyle et al (Journal of Virology 75:4792-4801, May 2001).*
Croyle et al. Human Gene Therapy 11:1713-1722, Aug. 10, 2000.*
Selma Mizouni, Viral Modification with Methoxypol (Ethylene Glycol): Implication for Viral Inactivation and Gene Therapy?, Thesis, Jul. 21, 2000, pp. i-59.
Selma Mizouni, Viral Modification with Methoxypoly(Ethylene Glycol): Implication for Viral Inactivation and Gene Therapy?, Thesis, Jun. 8, 2000, pp. i-59.
Mizouni et al., Viral Modification with Methoxypoly(Ethylene Glycol): Implications for Gene Therapy and Viral Inactivation, 1998, Blood 92 (Suppl. 1), 4627, 1 page.
Mizouni et al., Use of a Two-Phase Partitioning System to Purify an Immunologically Attenuated Viral Vector, 1999, Blood 94 (Suppl. 1) 5081 (415b), 1 page.
Albany Medical College
Mosher Mary E.
Schmeiser Olsen & Watts
LandOfFree
Enhancement of oligomeric viral immunogenicity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhancement of oligomeric viral immunogenicity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhancement of oligomeric viral immunogenicity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3169455